Technical Analysis for REPL - Replimune Group, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 6.81 | 1.49% | 0.10 |
REPL closed up 1.49 percent on Wednesday, May 15, 2024, on 62 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 16
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Gapped Up | Strength | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Crossed Above 20 DMA | Bullish | 1.49% | |
Bollinger Band Squeeze | Range Contraction | 1.49% | |
BB Squeeze Started | Range Contraction | 1.49% | |
20 DMA Resistance | Bearish | 3.34% | |
Fell Below 20 DMA | Bearish | 6.24% |
Alert | Time |
---|---|
Possible NR7 | about 14 hours ago |
Possible Inside Day | about 14 hours ago |
10 DMA Support | about 17 hours ago |
60 Minute Opening Range Breakdown | about 17 hours ago |
Fell Below 10 DMA | about 17 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/16/2024
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapy Products Oncolytic Virus Experimental Cancer Treatments Transgene Sa Akseli Hemminki Rp1
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapy Products Oncolytic Virus Experimental Cancer Treatments Transgene Sa Akseli Hemminki Rp1
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 24.81 |
52 Week Low | 5.86 |
Average Volume | 899,590 |
200-Day Moving Average | 11.38 |
50-Day Moving Average | 7.39 |
20-Day Moving Average | 6.60 |
10-Day Moving Average | 6.73 |
Average True Range | 0.42 |
RSI (14) | 48.98 |
ADX | 19.91 |
+DI | 18.21 |
-DI | 18.73 |
Chandelier Exit (Long, 3 ATRs) | 6.17 |
Chandelier Exit (Short, 3 ATRs) | 7.12 |
Upper Bollinger Bands | 7.06 |
Lower Bollinger Band | 6.13 |
Percent B (%b) | 0.73 |
BandWidth | 14.19 |
MACD Line | -0.15 |
MACD Signal Line | -0.22 |
MACD Histogram | 0.0655 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 7.17 | ||||
Resistance 3 (R3) | 7.18 | 7.07 | 7.11 | ||
Resistance 2 (R2) | 7.07 | 6.98 | 7.07 | 7.09 | |
Resistance 1 (R1) | 6.94 | 6.92 | 6.89 | 6.93 | 7.07 |
Pivot Point | 6.83 | 6.83 | 6.80 | 6.83 | 6.83 |
Support 1 (S1) | 6.70 | 6.74 | 6.65 | 6.69 | 6.55 |
Support 2 (S2) | 6.59 | 6.68 | 6.59 | 6.53 | |
Support 3 (S3) | 6.46 | 6.59 | 6.51 | ||
Support 4 (S4) | 6.45 |